Published in Medical Letter on the CDC and FDA, September 6th, 1999
The double-blinded, placebo-controlled trial, involving 1,800 end-stage renal disease patients on hemodialysis, has been fully accrued and will continue to completion. The company anticipates that final results will be available by next summer (2000). If these results demonstrate statistical significance, Nabi will pursue U.S. Food and Drug Administration (FDA) licensure.
"We are elated that the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA